The emerging field of epigenetics in neurodegeneration and neuroprotection

Nature Reviews Neuroscience

Volumn 18, Issue 6, 2017, Pages 347-361

  Hwang, Jee Yeon ^a   Aromolaran, Kelly A ^a   Zukin, R Suzanne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; POLYCOMB PROTEIN; PROTEIN; REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ALZHEIMER DISEASE; CELL DEATH; CEREBROVASCULAR ACCIDENT; COGNITION; DNA METHYLATION; EPIGENETICS; GLOBAL ISCHAEMIA; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HUNTINGTON CHOREA; ISCHEMIA; MEMORY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; ANIMAL; DEGENERATIVE DISEASE; GENETIC EPIGENESIS; GENETICS; TRENDS;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTION;

EID: 85019360968     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn.2017.46     Document Type: Review

References (156)

1. Waddington, C. H. The epigenotype. 1942. Int. J. Epidemiol. 41, 10-13 (2012).
2. Sweatt, J. D. The emerging field of neuroepigenetics. Neuron 80, 624-632 (2013).
3. Maze, I., Noh, K. M., Soshnev, A. A. & Allis, C. D. Every amino acid matters: essential contributions of histone variants to mammalian development and disease. Nat. Rev. Genet. 15, 259-271 (2014).
4. Piletic, K. & Kunej, T. MicroRNA epigenetic signatures in human disease. Arch. Toxicol. 90, 2405-2419 (2016).
5. Saeidimehr, S., Ebrahimi, A., Saki, N., Goodarzi, P. & Rahim, F. MicroRNA-based linkage between aging and cancer: from epigenetics view point. Cell J. 18, 117-126 (2016).
6. Leone, S. & Santoro, R. Challenges in the analysis of long noncoding RNA functionality. FEBS Lett. 590, 2342-2353 (2016).
7. Roberts, T. C., Morris, K. V. & Wood, M. J. The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease. Phil. Trans. R. Soc. B 369, 20130507 (2014).
8. Fagiolini, M., Jensen, C. L. & Champagne, F. A. Epigenetic influences on brain development and plasticity. Curr. Opin. Neurobiol. 19, 207-212 (2009).
9. Hwang, J. Y., Aromolaran, K. A. & Zukin, R. S. Epigenetic mechanisms in stroke and epilepsy. Neuropsychopharmacology 38, 167-182 (2013).
10. Day, J. J., Kennedy, A. J. & Sweatt, J. D. DNA methylation and its implications and accessibility for neuropsychiatric therapeutics. Annu. Rev. Pharmacol. Toxicol. 55, 591-611 (2015).
11. Landgrave-Gomez, J., Mercado-Gomez, O. & Guevara-Guzman, R. Epigenetic mechanisms in neurological and neurodegenerative diseases. Front. Cell. Neurosci. 9, 58 (2015).
12. Miller, C. A. & Sweatt, J. D. Covalent modification of DNA regulates memory formation. Neuron 53, 857-869 (2007).
13. Day, J. J. & Sweatt, J. D. DNA methylation and memory formation. Nat. Neurosci. 13, 1319-1323 (2010).
14. Graff, J., Kim, D., Dobbin, M. M. & Tsai, L. H. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol. Rev. 91, 603-649 (2011).
15. Feng, J., et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat. Neurosci. 13, 423-430 (2010).
16. Tahiliani, M., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009).
17. Kaas, G. A., et al. TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. Neuron 79, 1086-1093 (2013).
18. Levenson, J. M., et al. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J. Biol. Chem. 281, 15763-15773 (2006).
19. Swank, M. W. & Sweatt, J. D. Increased histone acetyltransferase and lysine acetyltransferase activity and biphasic activation of the ERK/RSK cascade in insular cortex during novel taste learning. J. Neurosci. 21, 3383-3391 (2001).
20. Levenson, J. M., et al. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279, 40545-40559 (2004).
21. Alarcon, J. M., et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42, 947-959 (2004).
22. Korzus, E., Rosenfeld, M. G. & Mayford, M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42, 961-972 (2004).
23. Bourtchouladze, R., et al. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl Acad. Sci. USA 100, 10518-10522 (2003).
24. Petrij, F., et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351 (1995).
25. Blough, R. I., et al. Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. Am. J. Med. Genet. 90, 29-34 (2000).
26. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M. & Tsai, L. H. Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178-182 (2007).
27. Calderone, A., et al. Ischaemic insults de-repress the gene silencer rest in neurons destined to die. J. Neurosci. 23, 2112-2121 (2003).
28. Noh, K. M., et al. Repressor element-1 silencing transcription factor (REST)-dependent epigenetic remodeling is critical to ischemia-induced neuronal death. Proc. Natl Acad. Sci. USA 109, E962-E971 (2012).
29. Ballas, N. & Mandel, G. The many faces of REST oversee epigenetic programming of neuronal genes. Curr. Opin. Neurobiol. 15, 500-506 (2005).
30. Ooi, L. & Wood, I. C. Chromatin crosstalk in development and disease: lessons from REST. Nat. Rev. Genet. 8, 544-554 (2007).
31. Baldelli, P. & Meldolesi, J. The transcription repressor REST in adult neurons: physiology, pathology, and diseases. eNeuro http://dx.doi.org/10.1523/ENEURO.0010-15.2015 (2015).
32. Bruce, A. W., et al. Genome-wide analysis of repressor element 1 silencing transcription factor/neuronrestrictive silencing factor (REST/NRSF) target genes. Proc. Natl Acad. Sci. USA 101, 10458-10463 (2004).
33. Conaco, C., Otto, S., Han, J. J. & Mandel, G. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc. Natl Acad. Sci. USA 103, 2422-2427 (2006).
34. Ballas, N., Grunseich, C., Lu, D. D., Speh, J. C. & Mandel, G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121, 645-657 (2005).
35. Rodenas-Ruano, A., Chavez, A. E., Cossio, M. J., Castillo, P. E. & Zukin, R. S. REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors. Nat. Neurosci. 15, 1382-1390 (2012).
36. Palm, K., Metsis, M. & Timmusk, T. Neuron-specific splicing of zinc finger transcription factor REST/NRSF/XBR is frequent in neuroblastomas and conserved in human, mouse and rat. Brain Res. Mol. Brain Res. 72, 30-39 (1999).
37. Huang, Y., Doherty, J. J. & Dingledine, R. Altered histone acetylation at glutamate receptor 2 and brainderived neurotrophic factor genes is an early event triggered by status epilepticus. J. Neurosci. 22, 8422-8428 (2002).
38. Formisano, L., et al. Ischemic insults promote epigenetic reprogramming of μ opioid receptor expression in hippocampal neurons. Proc. Natl Acad. Sci. USA 104, 4170-4175 (2007).
39. Formisano, L., et al. NCX1 is a new rest target gene: role in cerebral ischemia. Neurobiol. Dis. 50, 76-85 (2013).
40. Formisano, L., et al. Sp3/REST/HDAC1/HDAC2 complex represses and Sp1/HIF-1/p300 complex activates ncx1 gene transcription, in brain ischemia and in ischemic brain preconditioning, by epigenetic mechanism. J. Neurosci. 35, 7332-7348 (2015).
41. Zuccato, C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSEcontrolled neuronal genes. Nat. Genet. 35, 76-83 (2003).
42. Zuccato, C., et al. Widespread disruption of repressor element-1 silencing transcription factor/neuronrestrictive silencer factor occupancy at its target genes in Huntington's disease. J. Neurosci. 27, 6972-6983 (2007).
43. Schiffer, D., et al. Repressor element-1 silencing transcription factor (REST) is present in human control and Huntington's disease neurones. Neuropathol. Appl. Neurobiol. 40, 899-910 (2014).
44. Lu, T., et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 507, 448-454 (2014).
45. Perera, A., et al. TET3 is recruited by REST for context-specific hydroxymethylation and induction of gene expression. Cell Rep. 11, 283-294 (2015).
46. Guardavaccaro, D., et al. Control of chromosome stability by the β-TrCP-REST-Mad2 axis. Nature 452, 365-369 (2008).
47. Westbrook, T. F., et al. SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452, 370-374 (2008).
48. Singh, A., et al. Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCF(β-TRCP) in neuroblastoma cells. Cancer 117, 5189-5202 (2011).
49. Kaneko, N., Hwang, J. Y., Gertner, M., Pontarelli, F. & Zukin, R. S. Casein kinase 1 suppresses activation of REST in insulted hippocampal neurons and halts ischemia-induced neuronal death. J. Neurosci. 34, 6030-6039 (2014).
50. Huang, Z., et al. Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat. Cell Biol. 13, 142-152 (2011).
51. Zukin, R. S. Eradicating the mediators of neuronal death with a fine-tooth comb. Sci. Signal. 3, e20 (2010).
52. Stapels, M., et al. Polycomb group proteins as epigenetic mediators of neuroprotection in ischemic tolerance. Sci. Signal. 3, ra15 (2010).
53. Blackledge, N. P., Rose, N. R. & Klose, R. J. Targeting Polycomb systems to regulate gene expression: modifications to a complex story. Nat. Rev. Mol. Cell Biol. 16, 643-649 (2015).
54. Vire, E., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
55. Schlesinger, Y., et al. Polycomb-mediated methylation on lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232-236 (2007).
56. Schratt, G. MicroRNAs at the synapse. Nat. Rev. Neurosci. 10, 842-849 (2009).
57. Aksoy-Aksel, A., Zampa, F. & Schratt, G. MicroRNAs and synaptic plasticity - a mutual relationship. Phil. Trans. R. Soc. B 369, 20130515 (2014).
58. Woldemichael, B. T. & Mansuy, I. M. Micro-RNAs in cognition and cognitive disorders: potential for novel biomarkers and therapeutics. Biochem. Pharmacol. 104, 1-7 (2016).
59. Packer, A. N., Xing, Y., Harper, S. Q., Jones, L. & Davidson, B. L. The bifunctional microRNA miR-9/miR-9∗ regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28, 14341-14346 (2008).
60. Lusardi, T. A., et al. Ischemic preconditioning regulates expression of microRNAs and a predicted target, MeCP2, in mouse cortex. J. Cereb. Blood Flow Metab. 30, 744-756 (2010).
61. Hwang, J. Y., Kaneko, N., Noh, K. M., Pontarelli, F. & Zukin, R. S. The gene silencing transcription factor REST represses miR-132 expression in hippocampal neurons destined to die. J. Mol. Biol. 426, 3454-3466 (2014).
62. Tsai, M. C., et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329, 689-693 (2010).
63. Willert, J., Epping, M., Pollack, J. R., Brown, P. O. & Nusse, R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC. Dev. Biol. 2, 8 (2002).
64. Yu, M., et al. NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP. Neurobiol. Aging 34, 916-927 (2013).
65. De Jager, P. L., et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat. Neurosci. 17, 1156-1163 (2014).
66. Lunnon, K., et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat. Neurosci. 17, 1164-1170 (2014).
67. Chi, S., et al. Association of single-nucleotide polymorphism in ANK1 with late-onset Alzheimer's disease in Han Chinese. Mol. Neurobiol. 53, 6476-6481 (2016).
68. Birney, E., Smith, G. D. & Greally, J. M. Epigenomewide association studies and the interpretation of disease -omics. PLoS. Genet. 12, e1006105 (2016).
69. Mattson, M. P. Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (2004).
70. Savas, J. N., et al. Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc. Natl Acad. Sci. USA 105, 10820-10825 (2008).
71. Buckley, N. J., Johnson, R., Zuccato, C., Bithell, A. & Cattaneo, E. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol. Dis. 39, 28-39 (2010).
72. Conforti, P., et al. In vivo delivery of DN:REST improves transcriptional changes of REST-regulated genes in HD mice. Gene Ther. 20, 678-685 (2013).
73. von, S. M., et al. Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration. Nat. Neurosci. 19, 1321-1330 (2016).
74. Wang, F., et al. Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease. Hum. Mol. Genet. 22, 3641-3653 (2013).
75. Mozaffarian, D., et al. Heart Disease and Stroke Statistics-2016 Update: A report from the American Heart Association. Circulation 133, e38-e60 (2016).
76. Endres, M., Fan, G., Meisel, A., Dirnagl, U. & Jaenisch, R. Effects of cerebral ischemia in mice lacking DNA methyltransferase 1 in post-mitotic neurons. Neuroreport 12, 3763-3766 (2001).
77. Endres, M., et al. DNA methyltransferase contributes to delayed ischemic brain injury. J. Neurosci. 20, 3175-3181 (2000).
78. Annunziato, L., Pignataro, G. & Di Renzo, G. F. Pharmacology of brain Na+/Ca2+ exchanger: from molecular biology to therapeutic perspectives. Pharmacol. Rev. 56, 633-654 (2004).
79. Boscia, F., et al. Permanent focal brain ischemia induces isoform-dependent changes in the pattern of Na+/Ca2+ exchanger gene expression in the ischemic core, periinfarct area, and intact brain regions. J. Cereb. Blood Flow Metab. 26, 502-517 (2006).
80. Lanzillotta, A., et al. Targeted acetylation of NF-κB/RelA and histones by epigenetic drugs reduces postischemic brain injury in mice with an extended therapeutic window. Neurobiol. Dis. 49, 177-189 (2013).
81. Zhang, Z. G. & Chopp, M. Promoting brain remodeling to aid in stroke recovery. Trends Mol. Med. 21, 543-548 (2015).
82. Liu, X. S., Chopp, M., Zhang, R. L. & Zhang, Z. G. MicroRNAs in cerebral ischemia-induced neurogenesis. J. Neuropathol. Exp. Neurol. 72, 718-722 (2013).
83. Liu, X. S., et al. MicroRNA profiling in subventricular zone after stroke: miR-124a regulates proliferation of neural progenitor cells through Notch signaling pathway. PLoS ONE 6, e23461 (2011).
84. Liou, A. K., Clark, R. S., Henshall, D. C., Yin, X. M. & Chen, J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: A review on the stress-activated signaling pathways and apoptotic pathways. Prog. Neurobiol. 69, 103-142 (2003).
85. Moskowitz, M. A., Lo, E. H. & Iadecola, C. The science of stroke: mechanisms in search of treatments. Neuron 67, 181-198 (2010).
86. Ofengeim, D., Miyawaki, T. & Zukin, R. S. in Stroke: Pathophysiology, Diagnosis and Management 5th edn Ch. 6 (eds Mohr, J. P., et al.) 75-106 (Saunders, 2011).
87. Siegel, G., Saba, R. & Schratt, G. MicroRNAs in neurons: manifold regulatory roles at the synapse. Curr. Opin. Genet. Dev. 21, 491-497 (2011).
88. Wong, H. K., et al. De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease. Hum. Mol. Genet. 22, 3077-3092 (2013).
89. Lagos, D., et al. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat. Cell Biol. 12, 513-519 (2010).
90. DeWoskin, V. A. & Million, R. P. The epigenetics pipeline. Nat. Rev. Drug Discov. 12, 661-662 (2013).
91. Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. J. & Chiu, C. T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591-601 (2009).
92. Falkenberg, K. J., et al. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. Cell Death Differ. 23, 1209-1218 (2016).
93. Kazantsev, A. G. & Thompson, L. M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7, 854-868 (2008).
94. Green, K. N., et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 28, 11500-11510 (2008).
95. Hathorn, T., Snyder-Keller, A. & Messer, A. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease. Neurobiol. Dis. 41, 43-50 (2011).
96. d'Ydewalle, C., Bogaert, E. & Van Den Bosch, L. HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic 13, 771-779 (2012).
97. Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-1080 (2001).
98. Gardner, K. E., Allis, C. D. & Strahl, B. D. Operating on chromatin, a colorful language where context matters. J. Mol. Biol. 409, 36-46 (2011).
99. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6-21 (2002).
100. Kriaucionis, S. & Heintz, N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 929-930 (2009).
101. Tan, M., et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146, 1016-1028 (2011).
102. Jakovcevski, M. & Akbarian, S. Epigenetic mechanisms in neurological disease. Nat. Med. 18, 1194-1204 (2012).
103. Zovkic, I. B., Paulukaitis, B. S., Day, J. J., Etikala, D. M. & Sweatt, J. D. Histone H2A.Z subunit exchange controls consolidation of recent and remote memory. Nature 515, 582-586 (2014).
104. Maze, I., et al. Critical role of histone turnover in neuronal transcription and plasticity. Neuron 87, 77-94 (2015).
105. Tsankova, N., Renthal, W., Kumar, A. & Nestler, E. J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355-367 (2007).
106. Grimes, J. A., et al. The co-repressor mSin3A is a functional component of the REST-CoREST repressor complex. J. Biol. Chem. 275, 9461-9467 (2000).
107. Naruse, Y., Aoki, T., Kojima, T. & Mori, N. Neural restrictive silencer factor recruits mSin3 and histone deacetylase complex to repress neuron-specific target genes. Proc. Natl Acad. Sci. USA 96, 13691-13696 (1999).
108. Huang, Y., Myers, S. J. & Dingledine, R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat. Neurosci. 2, 867-872 (1999).
109. Zhang, Q., Piston, D. W. & Goodman, R. H. Regulation of corepressor function by nuclear NADH. Science 295, 1895-1897 (2002).
110. Lee, M. G., Wynder, C., Cooch, N. & Shiekhattar, R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437, 432-435 (2005).
111. Shi, Y. J. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19, 857-864 (2005).
112. Lunyak, V. V., et al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298, 1747-1752 (2002).
113. Battaglioli, E., et al. REST repression of neuronal genes requires components of the hSWI.SNF complex. J. Biol. Chem. 277, 41038-41045 (2002).
114. Ooi, L., Belyaev, N. D., Miyake, K., Wood, I. C. & Buckley, N. J. BRG1 chromatin remodeling activity is required for efficient chromatin binding by repressor element 1-silencing transcription factor (REST) and facilitates REST-mediated repression. J. Biol. Chem. 281, 38974-38980 (2006).
115. Cheong, J. K. & Virshup, D. M. Casein kinase 1: complexity in the family. Int. J. Biochem. Cell Biol. 43, 465-469 (2011).
116. Chen, H., et al. DNA damage regulates UHRF1 stability via the SCF(β-TrCP) E3 ligase. Mol. Cell. Biol. 33, 1139-1148 (2013).
117. Nesti, E., Corson, G. M., McCleskey, M., Oyer, J. A. & Mandel, G. C-Terminal domain small phosphatase 1 and MAP kinase reciprocally control REST stability and neuronal differentiation. Proc. Natl Acad. Sci. USA 111, E3929-E3936 (2014).
118. Pandey, U. B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447, 859-863 (2007).
119. McClelland, S., et al. The transcription factor NRSF contributes to epileptogenesis by selective repression of a subset of target genes. eLife 3, e01267 (2014).
120. Johnson, D. S., Mortazavi, A., Myers, R. M. & Wold, B. Genome-wide mapping of in vivo protein-DNA interactions. Science 316, 1497-1502 (2007).
121. Abrajano, J. J., et al. Corepressor for element-1-silencing transcription factor preferentially mediates gene networks underlying neural stem cell fate decisions. Proc. Natl Acad. Sci. USA 107, 16685-16690 (2010).
122. Mortazavi, A., Thompson, E. C., Garcia, S. T., Myers, R. M. & Wold, B. Comparative genomics modeling of the NRSF/REST repressor network: from single conserved sites to genome-wide repertoire. Genome Res. 16, 1208-1221 (2006).
123. Wu, C., et al. A forebrain ischemic preconditioning model established in C57Black/Crj6 mice. J. Neurosci. Methods 107, 101-106 (2001).
124. Tanaka, H., et al. Ischemic preconditioning: neuronal survival in the face of caspase-3 activation. J. Neurosci. 24, 2750-2759 (2004).
125. Miyawaki, T., et al. Ischemic preconditioning blocks BAD translocation, Bcl-xL cleavage, and large channel activity in mitochondria of postischemic hippocampal neurons. Proc. Natl Acad. Sci. USA 105, 4892-4897 (2008).
126. Takada, Y., et al. Mammalian Polycomb Scmh1 mediates exclusion of Polycomb complexes from the XY body in the pachytene spermatocytes. Development 134, 579-590 (2007).
127. Lee, K., et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J. Invest. Dermatol. 128, 9-17 (2008).
128. Chatoo, W., et al. The Polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J. Neurosci. 29, 529-542 (2009).
129. Lipinski, M. M., et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc. Natl Acad. Sci. USA 107, 14164-14169 (2010).
130. Zuccato, C. & Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311-322 (2009).
131. Shimojo, M. Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150Glued. J. Biol. Chem. 283, 34880-34886 (2008).
132. Dock, H., Theodorsson, A. & Theodorsson, E. DNA methylation inhibitor zebularine confers stroke protection in ischemic rats. Transl Stroke Res. 6, 296-300 (2015).
133. Kilgore, M., et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870-880 (2010).
134. Qing, H., et al. Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J. Exp. Med. 205, 2781-2789 (2008).
135. Chiu, C. T., Liu, G., Leeds, P. & Chuang, D. M. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36, 2406-2421 (2011).
136. Zadori, D., Geisz, A., Vamos, E., Vecsei, L. & Klivenyi, P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol. Biochem. Behav. 94, 148-153 (2009).
137. Wang, Z., Leng, Y., Tsai, L. K., Leeds, P. & Chuang, D. M. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: The roles of HDAC and MMP-9 inhibition. J. Cereb. Blood Flow Metab. 31, 52-57 (2011).
138. Liu, X. S., et al. Valproic acid increases white matter repair and neurogenesis after stroke. Neuroscience 220, 313-321 (2012).
139. Xuan, A., et al. Neuroprotective effects of valproic acid following transient global ischemia in rats. Life Sci. 90, 463-468 (2012).
140. Sadri-Vakili, G., et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 16, 1293-1306 (2007).
141. Ricobaraza, A., et al. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34, 1721-1732 (2009).
142. Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Perez-Otano, I. & Garcia-Osta, A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22, 1040-1050 (2012).
143. Cuadrado-Tejedor, M., Ricobaraza, A. L., Torrijo, R., Franco, R. & Garcia-Osta, A. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer's disease-like phenotype of a commonly used mouse model. Curr. Pharm. Des. 19, 5076-5084 (2013).
144. Giorgini, F., et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J. Biol. Chem. 283, 7390-7400 (2008).
145. Hockly, E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041-2046 (2003).
146. Faraco, G., et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70, 1876-1884 (2006).
147. Baltan, S., Bachleda, A., Morrison, R. S. & Murphy, S. P. Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia. Transl Stroke Res. 2, 411-423 (2011).
148. Zhang, Z. Y. & Schluesener, H. J. Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J. Neuropathol. Exp. Neurol. 72, 178-185 (2013).
149. Dompierre, J. P., et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571-3583 (2007).
150. Yildirim, F., et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp. Neurol. 210, 531-542 (2008).
151. Outeiro, T. F., et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519 (2007).
152. Luthi-Carter, R., et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl Acad. Sci. USA 107, 7927-7932 (2010).
153. Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F. & Fischer, A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 26, 187-197 (2011).
154. Ferrante, R. J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003).
155. Kim, H. J., Leeds, P. & Chuang, D. M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J. Neurochem. 110, 1226-1240 (2009).
156. Cruz, J. C. & Tsai, L. H. A. Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr. Opin. Neurobiol. 14, 390-394 (2004).